Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Joint National Committee 7 (JNC-7) defines resistant hypertension as a persistent elevation of blood pressure (BP) above goal - ≥ 140/90 mm Hg for the general hypertensive population or ≥ 130/80 mm Hg for persons with diabetes mellitus or chronic kidney disease - for at least three months despite treatment with three or more optimally dosed antihypertensive agents, including a diuretic. The exact prevalence of resistant hypertension is uncertain but may include 5-20% of hypertensive persons in primary care settings and 15-35% of the older, higher cardiovascular risk hypertensive patients incorporated into recent clinical trials of antihypertensive therapy. Observational studies demonstrate that patients with resistant hypertension experience a higher rate of cardiovascular and renal target organ damage such as left ventricular hypertrophy, microalbuminuria, and renal insufficiency and more cardiovascular disease (CVD) events than patients whose hypertension is well-controlled. Additionally, resistant hypertension patients may be subjected to the considerable expense of multiple office visits, diagnostic testing for secondary causes of hypertension, and referral to hypertension specialists. Because multiple factors can contribute to resistant hypertension, an explicit, sequential approach to evaluation and management is essential to optimize blood pressure, reduce cardiorenal morbidity and mortality, and avoid unnecessary expense. A number of observational studies have suggested the potential efficacy of both spironolactone and amiloride when added to a 3 drug antihypertensive regimen, but to date no randomized study has directly compared the two agents. The goal of this study is to determine whether spironolactone or amiloride is the more effective fourth agent to add to a three drug regimen in patients with resistant hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

NCT01195805

Essential Hypertension

COMPLETED NA

The Effect of Amiloride and Spironolactone in Patients With Hypertension

NCT01388088

Hypertension

COMPLETED PHASE4

The Efficacy of Spironolactone in Patients With Resistant Hypertension

NCT00430794

Hypertension

TERMINATED PHASE2

The Effect of Amiloride and Spironolactone in Healthy Persons

NCT00857909

High Blood Pressure

COMPLETED PHASE1

Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD

NCT02502981

Renal Insufficiency, Chronic Cardio-Renal Syndrome

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

m/a

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)

Group Type ACTIVE_COMPARATOR

spironolactone

Intervention Type DRUG

tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.

2

this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)

Group Type ACTIVE_COMPARATOR

amiloride

Intervention Type DRUG

amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

spironolactone

tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.

Intervention Type DRUG

amiloride

amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

aldactone midamor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants will be selected from a broad range of medical clinics at the Salt Lake City VA Medical Center and surrounding community based outpatient clinics (CBOCs).
* The participants will be referred to a resistant hypertension clinic by either their primary care provider or by a subspecialist. The referrals are made via a computerized system that is used in the Veterans Affairs Medical Center (VA) called Computerized Patient Record System (CPRS).
* Patients are referred if their blood pressure is above goal as defined by JNC 7 and they are on 3 antihypertensive medications with one of the agents being a diuretic.
* All patients age 18 -80 years old.

Exclusion Criteria

* Patients that will be excluded from the study if they have had a documented adverse reaction to either spironolactone or amiloride.
* diagnosis of primary hyperaldosteronism
* inability to adhere to frequent laboratory monitoring
* estimated glomerular filtration rate (GFR) \< 45 ml/min/1.73m2
* baseline serum potassium above 5.0 mEq/L
* type 4 renal tubular acidosis
* pregnancy
* heart failure that meets criteria for using either eplerenone or spironolactone
* current unstable renal function

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes